Ticker

Analyst Price Targets — HITI

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
February 27, 2023 11:37 amCantor Fitzgerald’sCantor Fitzgerald$2.70$1.36Benzinga Cantor Fitzgerald Lowers Price Target On High Tide Stock

Latest News for HITI

High Tide CEO Raj Grover Answered Shareholder Questions During Reddit AMA

CALGARY, AB, July 15, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, is pleased to announce that Founder & Chief Executive Officer Raj Grover answered shareholder questions during his fifth Reddit Ask Me Anything ("AMA") session today, on July…

PRNewsWire • Jul 15, 2026
High Tide Announces Adoption of New Shareholder Rights Plans

CALGARY, AB, July 6, 2026 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan agreement (the "Temporary Shareholder Rights Plan"), and an…

PRNewsWire • Jul 6, 2026
High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026

CALGARY, AB, June 17, 2026 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its majority-owned subsidiary, Remexian Pharma GmbH ("Remexian"), showcased its exclusive German medical cannabis distribution partnerships with leading…

PRNewsWire • Jun 17, 2026
High Tide Reports Second Quarter 2026 Financial Results Featuring Record Revenue of $179.3MM, and Adjusted EBITDA of $13.9MM

The Company Also Reports Positive Free Cash Flow and Net Income The Company's German Medical Cannabis Subsidiary, Remexian Pharma GmbH (Remexian) Generated Record Revenue of $31.6 Million with Gross Margins Increasing to 27% The Company Has Secured Credit Approval with Bank of Montreal for $40MM of Senior Secured Credit Facilities to Fuel Further Non-Dilutive Growth Canadian Cabana Club Membership Now Exceeds 2.65…

PRNewsWire • Jun 15, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for HITI.

No Senate trades found for HITI.

No House trades found for HITI.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top